Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Safety of Campath-1H as an Induction Agent in Combination With Tacrolimus Monotherapy for Prevention of Graft Rejection Compared to Tacrolimus in Combination With MMF and Steroids in Cadaveric Kidney Transplantation
Brief Summary: The purpose of this study is to determine whether Campath following Tacrolimus monotherapy is more effective in the prevention of renal graft rejection (considering an acute rejection rate of 5% for Campath-1H/Tacrolimus and of 22% for Tacrolimus/MMF/Steroids).


Options:
A: Arm Label: Alemtuzumab High-Risk Patients; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus, Drug: alemtuzumab, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Conventional High-Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Drug: rabbit anti-thymocyte globulin, Drug: tacrolimus, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Alemtuzumab Low- Risk Patients; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus, Drug: alemtuzumab, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Conventional Low-Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Drug: basiliximab, Drug: tacrolimus, Drug: mycophenolate mofetil, Drug: steroids | Intervention Type: DRUG; Name: basiliximab; Assigned to Arm(s): Conventional Low-Risk Patients | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin; Assigned to Arm(s): Conventional High-Risk Patients | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients | Intervention Type: DRUG; Name: alemtuzumab; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients | Intervention Type: DRUG; Name: steroids; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients
B: Arm Label: Single-dose Thymoglobulin; Type: EXPERIMENTAL; Interventions: Biological: Single-dose rabbit Anti-thymocyte Globulin induction | Arm Label: Divided-dose Thymoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Biological: Divided-dose rabbit Anti-thymocyte Globulin induction | Intervention Type: BIOLOGICAL; Name: Single-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Single-dose Thymoglobulin | Intervention Type: BIOLOGICAL; Name: Divided-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Divided-dose Thymoglobulin
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Campath-1H 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus | Arm Label: Campath-1H 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 20 mg | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 30 mg

Answer: D